Information Provided By: 
Fly News Breaks for June 29, 2017
MYGN
Jun 29, 2017 | 07:26 EDT
With the shares up 30% over the past month, JPMorgan analyst Tycho Peterson maintains an Underweight rating on Myriad Genetics with a $16 price target. While the company's pipeline "intriguing," it is not enough to offset a continued decline in the core hereditary cancer business, Peterson tells investors in a research note. He believes near-term catalysts could drive the stock "meaningfully higher or lower," and highlights the FY18 guidance in the Q4 earnings report as being the most significant upcoming event.
News For MYGN From the Last 2 Days
There are no results for your query MYGN
